Skip to main content
Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 7.99
Day High 8.07
Open:8.04
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Knight Partners with Debiopharm for the Commercialization of Trelstar(R) in Canada
- GlobeNewswire - Wed Jan 8, 7:00AM CST
GlobeNewswire - CMTX
Wed Jan 8, 7:00AM CST
Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company and Debiopharm , a swiss-based, global biopharmaceutical company, today announced that they have entered into an exclusive agreement that grants Knight the rights to commercialize Trelstar(R) (triptorelin) in Canada. Knight expects to take over commercial activities from Debiopharm's current partner Allergan and begin recording revenues in early 2020. Previously, Trelstar(R) was successfully launched and commercialized in Canada by Paladin Labs Inc. between 2006 to 2014.
Knight Partners With Debiopharm for the Commercialization of Trelstar® in Canada
- PR Newswire - Wed Jan 8, 7:00AM CST
PR Newswire - PRNW
Wed Jan 8, 7:00AM CST
MONTREAL and LAUSANNE, Switzerland , Jan. 8, 2020 /PRNewswire/ -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex- USA ) specialty pharmaceutical company and Debiopharm, a Swiss-based, global biopharmaceutical company, today announced that they have entered into an exclusive agreement that grants Knight the rights to commercialize Trelstar® (triptorelin) in Canada . Knight expects to take over commercial activities from Debiopharm's current partner Allergan and begin recording revenues in early 2020. Previously, Trelstar® was successfully launched and commercialized in Canada by Paladin Labs Inc. between 2006 to 2014.
Knight to Present at the J.P. Morgan Healthcare Conference in San Francisco
- GlobeNewswire - Tue Jan 7, 3:30PM CST
GlobeNewswire - CMTX
Tue Jan 7, 3:30PM CST
Knight Therapeutics Inc. (TSX: GUD) ("Knight") a leading pan-American (ex-USA) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Financial Officer, is scheduled to present at the J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 4:30 PM PST at the Westin St. Francis Hotel in San Francisco. A copy of the presentation will be available at www.gud-knight.com.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 7.56 +5.82% increase
on 01/08/20
Period Open:7.68
Price movement based on the high, low and last over the given period.
8.12 -1.48% decrease
on 01/16/20
+0.32 (+4.17%) increase
since 12/24/19
3-Month 7.40 +8.11% increase
on 12/17/19
Period Open:8.49
Price movement based on the high, low and last over the given period.
8.56 -6.54% decrease
on 10/25/19
-0.49 (-5.77%) decrease
since 10/24/19
52-Week 7.10 +12.68% increase
on 05/03/19
Period Open:8.02
Price movement based on the high, low and last over the given period.
8.88 -9.91% decrease
on 10/23/19
-0.02 (-0.25%) decrease
since 01/24/19

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies